DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Isatuximab
Isatuximab
FDA Updates Highlighting the Latest Cancer Treatments
New Drug Updates Brendan Mangan, Pharmd Clinical Pharmacy Specialist Hospital of the University of Pennsylvania
Immunotherapies Shape the Treatment Landscape for Hematologic Malignancies Jane De Lartigue, Phd
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Sarclisa, INN-Isatuximab
Provider Newsletter April 2021
Northwest Medical Benefit Formulary (List of Covered Drugs) Please Read
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Sanofi Genzyme Booklet
Multiple Sclerosis: Current and Pipeline Treatments and Their Impact
Formulary Drug List
Oncology Dose Reduction Program Beginning July 1, 2021
Clinician's Guide to COVID-19 Vaccination for Patients with Cancer
Australian Public Assessment Report for Isatuximab
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
Injectable Anti-Cancer Medications
Prophylaxis Guidelines for the Adult Hematology Patient
North Carolina Division of Health Benefits Physician Administered Drug Program Catalog
Top View
Crizanlizumab-Tmca
Pipeline Report May 2020
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Individualized Genetic Makeup That Controls Natural Killer Cell Function Influences the Efficacy of Isatuximab Immunotherapy in Patients with Multiple Myeloma
Statement on Future Research and Therapies For
The Many Facets of CD38 in Lymphoma: from Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
Isatuximab-Irfc (Sarclisa®)
5.01.540 (Effective Nov. 5, 2021) Miscellaneous Oncology Drugs
Prescribed Drugs Physician Administered Billing Codes
Isatuximab with Pomalidomide and Dexamethasone for Treating Relapsed Or Refractory Multiple Myeloma
Q2 2019 Clinical Trials Appendices
Cardiotoxicity of Novel Targeted Hematological Therapies
Newsletter: Human Medicines Highlights
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells
Therapeutic Advances in Oncology
Isatuximab-Irfc) Injection, for Intravenous Use Second Primary Malignancies (SPM): Monitor Patients for the Initial U.S
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
Clinical Cancer Advances 2021: ASCO's Report on Progress Against
CLINICAL TRIAL ANNOUNCEMENT Phase I /II Trial to Evaluate Isatuximab in Patients with Advanced Malignancies
Adult Antiemetic Management of Chemotherapy-Induced Nausea
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Resistance Mechanisms Towards CD38−Directed Antibody Therapy in Multiple Myeloma
R&D Pipeline – New Molecular Entities
Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
Isatuximab with Pomalidomide and Dexamethasone
The Royal Marsden NHS Foundation Trust Drug & Therapeutic Committee Minutes 28Th April 2020
VIRGINIA Provider Communications
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody
Highly Sensitized Transplant Candidate
Oncology Therapy for the Generalist
New Century Health Policy Changes March 2021
The Mechanism of Action of the Anti-Cd38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Sarclisa® (Isatuximab-Irfc)
PDF of Antibody News
Services That Require Precertification Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services
A Phase 2 Study of Isatuximab Monotherapy in Patients With
Why Immunotherapy Fails in Multiple Myeloma
International Nonproprietary Names for Pharmaceutical Substances (INN)
Crizanlizumab-Tmca
Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
Review Article Selection of New Immunotherapy Targets for NK/T Cell Lymphoma
Changes to Cancer Care Quality Program Effective May 17, 2021
Generic (Brand) Name Mechanism of Action Mechanism of Action
Full Prescribing Information [FDA]
MORPHEUS: a Phase Ib/II Study Platform Evaluating The
Therapeutic Monoclonal Antibodies & Blood Transfusion
Download Overview
Isatuximab (Interim Monograph)
Review Papers ESMO/EHA/ESTRO 2019, Presented by the Mentees of the Young Oncology Academy 2019
Monoclonal Antibodies in Cancer Therapy
Diplomat Specialty Pipeline Report
761113Orig1s000
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
CALIFORNIA Provider Communications
Amended Clinical Trial Protocol 13
Therapeutic Monoclonal Antibodies Approved by FDA in 2020 Henry Hongrong Cai, MD
Pre - PA Allowance None ______
Anti-CD38 Monoclonal Antibodies in the Treatment of Multiple Myeloma
Antibodies to Watch in 2018